The Global Chemiluminescence Immunoassay (CLIA) Analyzers Market is projected to reach $ 10,781.39 million by 2028, from a value of $6,645.05 million in 2022, by registering a CAGR of 8.4% during the forecast period. The rising prevalence of chronic and acute diseases, increasing rapid technological advancement, and rapid changes in eating habits and lifestyle is the reason behind the increasing rate of chronic diseases such as cancer, therefore, the increasing prevalence of acute and chronic diseases are the major factors propelling the growth of the market. However, the lack of skilled labor or trained professionals, and stringent regulatory policies are hampering the market growth. Moreover, high specificity and technological advancements are creating ample opportunities across the globe.
Recent Developments
In June 2020, Abbott announced that it has begun supply of its laboratory-based serology blood test for the detection of the antibody, IgG for identification if COVID-19. This is enabled to contribute to ICMRs COVID-19 antibody testing strategy to use IgG CLIA antibody tests.
In December 2021, Pfizer In and Arena Pharmaceuticals, Inc have announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
In July 2018 DiaSorin announced that it had received clearance from the CE Notified Body to market the LIAISON® XL Murex Anti-HDV assay for the diagnosis of Hepatitis D virus (HDV) infection enlarging its CLIA menu for hepatitis on LIAISON® platforms..
Competitive Landscape
Abbott Laboratories, Beckman Coulter, Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Randox Laboratories Ltd., Shenzhen New Industries Biomedical Engineering Co., Ltd., Siemens Healthineers
Sysmex Corporation, Tosoh Corporation, DiaSorin, Pfizer are some of the major players in the Global Chemiluminescence Immunoassay (CLIA) Analyzers Market.
